47,065 Shares in Stevanato Group S.p.A. (NYSE:STVN) Acquired by William Blair Investment Management LLC

William Blair Investment Management LLC purchased a new stake in Stevanato Group S.p.A. (NYSE:STVN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 47,065 shares of the company’s stock, valued at approximately $1,026,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in STVN. Royce & Associates LP grew its stake in shares of Stevanato Group by 33.6% in the fourth quarter. Royce & Associates LP now owns 458,335 shares of the company’s stock worth $9,987,000 after purchasing an additional 115,176 shares during the last quarter. Natixis Advisors LLC lifted its holdings in Stevanato Group by 5.4% during the 4th quarter. Natixis Advisors LLC now owns 54,128 shares of the company’s stock worth $1,179,000 after buying an additional 2,785 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Stevanato Group by 1,457.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock valued at $123,000 after buying an additional 5,291 shares during the last quarter. Marco Investment Management LLC bought a new position in shares of Stevanato Group during the fourth quarter worth about $203,000. Finally, Raymond James Financial Inc. bought a new position in shares of Stevanato Group during the fourth quarter worth about $5,754,000.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on STVN. William Blair reissued an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Bank of America upped their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. UBS Group lowered their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of €27.75 ($30.16).

Stevanato Group Trading Down 0.1 %

STVN opened at €21.74 ($23.63) on Thursday. The company has a fifty day moving average price of €21.08 and a two-hundred day moving average price of €20.59. Stevanato Group S.p.A. has a 1-year low of €16.56 ($18.00) and a 1-year high of €33.49 ($36.40). The company has a market cap of $6.58 billion, a P/E ratio of 46.26, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The business had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.